An insight into aptamer engineered dendrimer for cancer therapy

被引:53
作者
Sheikh, Afsana [1 ]
Kesharwani, Prashant [1 ]
机构
[1] Jamia Hamdard, Dept Pharmaceut, Sch Pharmaceut Educ & Res, New Delhi 110062, India
关键词
Aptamer; Dendrimer; Cancer; Target drug delivery; Gene delivery; Nanomaterials; TARGETED DELIVERY; IN-VITRO; PAMAM DENDRIMERS; DRUG-DELIVERY; 3,4-DIFLUOROBENZYLIDENE CURCUMIN; PROMISING NANOCARRIERS; CONTROLLED-RELEASE; PROSTATE-CANCER; GENE DELIVERY; NANOPARTICLES;
D O I
10.1016/j.eurpolymj.2021.110746
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Aptamers play an important role in biomedical industry due to their great affinity to bind to target site. Due to their targeting potency, an adequate amount of therapeutically active drug could be internalized inside the tumor cells. However, development of functionalized aptamer is hindered due to degradation by endonuclease. A bioconjugation of aptamer based dendrimer delivery could grant a new platform of improved targeted drug delivery system. Dendrimers are synthetic molecule with high ligand binding capability due to presence of enormous functional group on their periphery. Unlike other class of polymer, they serve as a biocompatible and stable vehicle with high drug loading efficiency. In this review, we have discussed about the role of aptamer in pharmaceutical industry along with potential of dendrimer as a novel carrier having high ligand binding capability. The review majorly focused on delivery of anticancer drugs and genetic agents to various neoplastic cells.
引用
收藏
页数:13
相关论文
共 127 条
[81]   Aptamer Therapeutics in Cancer: Current and Future [J].
Morita, Yoshihiro ;
Leslie, Macall ;
Kameyama, Hiroyasu ;
Volk, David E. ;
Tanaka, Takemi .
CANCERS, 2018, 10 (03)
[82]   Evaluation of dendrimer type bio-reducible polymer as a siRNA delivery carrier for cancer therapy [J].
Nam, Joung-Pyo ;
Nam, Kihoon ;
Jung, Simhyun ;
Nah, Jae-Woon ;
Kim, Sung Wan .
JOURNAL OF CONTROLLED RELEASE, 2015, 209 :179-185
[83]   Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes [J].
Ni, Shuaijian ;
Yao, Houzong ;
Wang, Lili ;
Lu, Jun ;
Jiang, Feng ;
Lu, Aiping ;
Zhang, Ge .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
[84]   Aptamers: An emerging class of therapeutics [J].
Nimjee, SM ;
Rusconi, CP ;
Sullenger, BA .
ANNUAL REVIEW OF MEDICINE, 2005, 56 :555-+
[85]   Aptasensors - the future of biosensing [J].
O'Sullivan, CK .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2002, 372 (01) :44-48
[86]   Aptamers Chemistry: Chemical Modifications and Conjugation Strategies [J].
Odeh, Fadwa ;
Nsairat, Hamdi ;
Alshaer, Walhan ;
Ismail, Mohammad A. ;
Esawi, Ezaldeen ;
Qaqish, Baraa ;
Al Bawab, Abeer ;
Ismail, Said I. .
MOLECULES, 2020, 25 (01)
[87]   Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells [J].
Otis, James B. ;
Zong, Hong ;
Kotylar, Alina ;
Yin, Anna ;
Bhattacharjee, Somnath ;
Wang, Han ;
Baker, James R., Jr. ;
Wang, Su He .
ONCOTARGET, 2016, 7 (24) :36002-36013
[88]   Dendrimers and hyperbranched structures for biomedical applications [J].
Pedziwiatr-Werbicka, Elzbieta ;
Milowska, Katarzyna ;
Dzmitruk, Volha ;
Ionov, Maksim ;
Shcharbin, Dzmitry ;
Bryszewska, Maria .
EUROPEAN POLYMER JOURNAL, 2019, 119 :61-73
[89]   Nanocarriers as an emerging platform for cancer therapy [J].
Peer, Dan ;
Karp, Jeffrey M. ;
Hong, SeungPyo ;
FaroKHzad, Omid C. ;
Margalit, Rimona ;
Langer, Robert .
NATURE NANOTECHNOLOGY, 2007, 2 (12) :751-760
[90]   Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers [J].
Prodeus, Aaron ;
Abdul-Wahid, Aws ;
Fischer, Nicholas W. ;
Huang, Eric H-B ;
Cydzik, Marzena ;
Gariepy, Jean .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2015, 4 :e237